Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carl H June

Showing results (371-380 of 460) with videos related to

Pageof 46
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 8, 2018
Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic LeukemiaKaren Thudium Mueller, Edward Waldron, Stephan A Grupp, et al.
Nature Medicine|November 11, 2008
Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptorAngel Varela-Rohena, Peter E Molloy, Steven M Dunn, et al.
Nature|September 25, 2024
Single-cell CAR T atlas reveals type 2 function in 8-year leukaemia remissionZhiliang Bai, Bing Feng, Susan E McClory, et al.
Blood Immunology & Cellular Therapy|April 17, 2026
Viral vector-free generation of orthogonal IL-2-responsive CAR T cells through gene editing of IL-2 and its receptorQian Zhang, Yihao Wu, Jingyi Yang, et al.
Science Translational Medicine|July 21, 2017
A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastomaDonald M O'Rourke, MacLean P Nasrallah, Arati Desai, et al.
Blood|May 12, 2016
Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapyVijay G Bhoj, Dimitrios Arhontoulis, Gerald Wertheim, et al.
The Journal of Clinical Investigation|August 30, 2016
Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapiesMarco Ruella, David M Barrett, Saad S Kenderian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2011
Phase I trial of adoptive cell transfer with mixed-profile type-I/type-II allogeneic T cells for metastatic breast cancerNancy M Hardy, Miriam E Mossoba, Seth M Steinberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2009
Rapid immune recovery and graft-versus-host disease-like engraftment syndrome following adoptive transfer of Costimulated autologous T cellsAaron P Rapoport, Edward A Stadtmauer, Nicole Aqui, et al.
Immunity|June 23, 2016
Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control AdenocarcinomaAvery D Posey, Robert D Schwab, Alina C Boesteanu, et al.
Pageof 46

Showing results (371-380 of 460) with videos related to

Sort By:
Pageof 46
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 8, 2018
Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic LeukemiaKaren Thudium Mueller, Edward Waldron, Stephan A Grupp, et al.
Nature Medicine|November 11, 2008
Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptorAngel Varela-Rohena, Peter E Molloy, Steven M Dunn, et al.
Nature|September 25, 2024
Single-cell CAR T atlas reveals type 2 function in 8-year leukaemia remissionZhiliang Bai, Bing Feng, Susan E McClory, et al.
Blood Immunology & Cellular Therapy|April 17, 2026
Viral vector-free generation of orthogonal IL-2-responsive CAR T cells through gene editing of IL-2 and its receptorQian Zhang, Yihao Wu, Jingyi Yang, et al.
Science Translational Medicine|July 21, 2017
A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastomaDonald M O'Rourke, MacLean P Nasrallah, Arati Desai, et al.
Blood|May 12, 2016
Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapyVijay G Bhoj, Dimitrios Arhontoulis, Gerald Wertheim, et al.
The Journal of Clinical Investigation|August 30, 2016
Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapiesMarco Ruella, David M Barrett, Saad S Kenderian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2011
Phase I trial of adoptive cell transfer with mixed-profile type-I/type-II allogeneic T cells for metastatic breast cancerNancy M Hardy, Miriam E Mossoba, Seth M Steinberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2009
Rapid immune recovery and graft-versus-host disease-like engraftment syndrome following adoptive transfer of Costimulated autologous T cellsAaron P Rapoport, Edward A Stadtmauer, Nicole Aqui, et al.
Immunity|June 23, 2016
Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control AdenocarcinomaAvery D Posey, Robert D Schwab, Alina C Boesteanu, et al.
Pageof 46